BACKGROUND: High ATP-binding cassette (ABC) protein expression leads to intrinsic drug resistance of hepatocellular carcinoma (HCC). The aim of this study was to investigate the potential chemosensitizing effects of sorafenib on the multi-drug resistance (MDR) phenotype. MATERIAL AND METHODS: The ABC-protein gene expression and the cellular survival were determined by RT-PCR analysis and MTT assay in HUH7 cells. RESULTS: Sorafenib inhibits MDR. The ABC-protein mRNA expression decreased by up to 51% (p ≤ 0.01). Addition of sorafenib to conventional chemotherapy restored the chemosensitivity. Combination of gemcitabine plus sorafenib decreased the ABC-protein mRNA levels by up to 77%, compared to gemcitabine monotherapy (p ≤ 0.001). Doxorubicin plus sorafenib decreased the ABC-protein mRNA levels up to 74% compared to doxorubicin monotherapy (p ≤ 0.001). CONCLUSION: This study provides evidence that the MDR phenotype of HCC cells can be modulated by the multi-kinase inhibitor sorafenib and consequentially may lead towards personalized therapies in patients with highly resistant tumors.
BACKGROUND: High ATP-binding cassette (ABC) protein expression leads to intrinsic drug resistance of hepatocellular carcinoma (HCC). The aim of this study was to investigate the potential chemosensitizing effects of sorafenib on the multi-drug resistance (MDR) phenotype. MATERIAL AND METHODS: The ABC-protein gene expression and the cellular survival were determined by RT-PCR analysis and MTT assay in HUH7 cells. RESULTS:Sorafenib inhibits MDR. The ABC-protein mRNA expression decreased by up to 51% (p ≤ 0.01). Addition of sorafenib to conventional chemotherapy restored the chemosensitivity. Combination of gemcitabine plus sorafenib decreased the ABC-protein mRNA levels by up to 77%, compared to gemcitabine monotherapy (p ≤ 0.001). Doxorubicin plus sorafenib decreased the ABC-protein mRNA levels up to 74% compared to doxorubicin monotherapy (p ≤ 0.001). CONCLUSION: This study provides evidence that the MDR phenotype of HCC cells can be modulated by the multi-kinase inhibitor sorafenib and consequentially may lead towards personalized therapies in patients with highly resistant tumors.
Authors: Silvia Di Giacomo; Marco Gullì; Roberta Facchinetti; Marco Minacori; Romina Mancinelli; Ester Percaccio; Caterina Scuderi; Margherita Eufemi; Antonella Di Sotto Journal: Pharmaceutics Date: 2022-06-14 Impact factor: 6.525
Authors: Shaymaa M M Yahya; Shadia A Fathy; Zakaria A El-Khayat; Safinaz E El-Toukhy; Ahmed R Hamed; Marwa G A Hegazy; Heba K Nabih Journal: Indian J Clin Biochem Date: 2017-04-21
Authors: Ekaterina V Malofeeva; Natalya Domanitskaya; Mariya Gudima; Elizabeth A Hopper-Borge Journal: Cancer Res Date: 2012-10-19 Impact factor: 12.701
Authors: Shibo Lin; Katrin Hoffmann; Zhi Xiao; Nan Jin; Uwe Galli; Elvira Mohr; Markus W Büchler; Peter Schemmer Journal: Cancer Cell Int Date: 2013-01-15 Impact factor: 5.722
Authors: Ariel Ka-Man Chow; Lui Ng; Colin Siu-Chi Lam; Sunny Kit-Man Wong; Timothy Ming-Hun Wan; Nathan Shiu-Man Cheng; Thomas Chung-Cheung Yau; Ronnie Tung-Ping Poon; Roberta Wen-Chi Pang Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Rodrigo Dos Santos Horta; Antonio Giuliano; Gleidice Eunice Lavalle; Mariana de Pádua Costa; Roberto Baracat de Araújo; Fernando Constantino-Casas; Jane Margaret Dobson Journal: Oncol Lett Date: 2017-11-01 Impact factor: 2.967